Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05437328 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05437328 · ClinicalTrials.gov record · last posted 2026-08-24

GD2/CD56 Bi-specific CAR-T Cell Therapy

Name: GD2/CD56 Bi-specific CAR-T Cell Therapy — clinical trial record (NCT05437328)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 1/2

SponsorShenzhen Geno-Immune Medical Institute

Started2026-06-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.

Protocol amendment history 3 changes detected by DataLookout

2026-08-25

Trial terminated

2026-08-25

Primary completion moved earlier: 2029-12-31 → 2026-07-01

2026-08-25

Completion moved earlier: 2030-12-31 → 2026-07-31

Trial Details

NCT Number	NCT05437328
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Malignant Disease
Enrollment	60 participants
Start Date	2026-06-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-24